Floatz logo

Everolimus

Advanced Solid Tumors

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanySmall moleculePhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
59/ 100

Competitive context

1411 Active assets in the Advanced Solid Tumors cohort.

View all 50

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →